GPCRsin pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets

Pancreatic cancer has one of the highest mortality rates (5‐year survival ~9%) among cancers. Pancreatic adenocarcinoma (PAAD) is the most common (>80%) and the most lethal type of pancreatic cancer. A need exists for new approaches to treat pancreatic adenocarcinoma. GPCRs, the largest family of cell‐surface receptors and drug targets, account for ~35% of approved drugs. Recent studies have revealed roles for GPCRs in PAAD cells and cells in...